New molecular understanding of mental disorders through deep cerebrospinal fluid phenotyping

This project aims to revolutionize psychiatry by conducting unprecedented deep phenotyping of cerebrospinal fluid to identify novel therapeutic targets and enhance understanding of mental disorders.

Subsidie
€ 1.499.070
2024

Projectdetails

Introduction

Psychiatry is lacking truly objective markers, and the limited molecular understanding of disease mechanisms underlying mental disorders inhibits us from designing new therapies. The identification of novel treatment targets is urgently needed. No study has yet conducted deep phenotyping of the cerebrospinal fluid (CSF), which is the biological material closest to the brain that is assessable for direct investigations in vivo. Additionally, no large longitudinal CSF studies on mental disorders currently exist.

Project Aim

I aim at a paradigm change by advancing the current state-of-the-art through novel deep CSF phenotyping on unique CSF samples from individuals with:

  1. First episode psychotic disorders
  2. Depression
  3. Healthy controls

This will be followed up longitudinally, both clinically and in nationwide registers.

Methodology

Pushing the frontiers of knowledge within psychiatry, I will use novel technologies and, for the first time for these disorders, employ cutting-edge single-cell sequencing of cell compartments in the CSF potentially involved in or affected by disease, with a particular focus on T cell alterations.

For the first time, longitudinal omics analyses will be conducted with:

  • Targeted metabolomics
  • Untargeted metabolomics
  • Proteomics

These analyses aim to identify disease-relevant metabolites and proteins in the CSF, thereby increasing the understanding of molecular mechanisms of psychiatric symptoms and diagnosis.

Analytical Approaches

Systems biology and deep learning approaches will provide crucial insights into biological pathways and the interplay between brain pathophysiological mechanisms in a cross-diagnostic manner. This may potentially identify biologically distinct clusters and disentangle the involved molecular mechanisms.

Significance

This approach is unprecedented. The identification of novel therapeutic targets, increasing the understanding of mental disorders, and insights into molecular mechanisms through deep CSF phenotyping has groundbreaking potential for psychiatry and neuroscience, paving the way for more effective and mechanism-based treatment.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.070
Totale projectbegroting€ 1.499.070

Tijdlijn

Startdatum1-12-2024
Einddatum30-11-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • REGION HOVEDSTADENpenvoerder

Land(en)

Denmark

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.

This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors.

€ 2.999.934
ERC Starting...

Transcriptional Regulation Assessed in Neuronal Subtypes in three major interrelated Psychiatric disorders

The project aims to develop brain organoid models for schizophrenia, bipolar disorder, and major depression by identifying and targeting key upstream transcription factors using multi-omics profiling.

€ 1.499.999
ERC Starting...

Mental illness, substance use, and cardiovascular disease: Unravelling causal relationships

This project aims to clarify the bidirectional relationships between serious mental illness and its comorbidities using innovative epidemiological methods to enhance prevention and treatment strategies.

€ 1.500.000
ERC Consolid...

Altered brain-periphery crosstalk as a key pathomechanism for high-risk phenotypes in humans

This project aims to elucidate the role of altered brain-periphery communication in identifying high-risk diabetes phenotypes to enhance prevention and treatment strategies.

€ 1.999.838
ERC Starting...

Identifying the Fast-acting Antidepressant Signatures of Treatment Response with psychedelic compounds using a novel behavioral tracking system and single-cell resolution

FASTer aims to revolutionize behavioral neuroscience by using advanced tracking and molecular techniques to identify brain circuits and genes involved in the rapid antidepressant effects of psilocybin.

€ 1.500.000

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Revolutionary high-resolution human 3D brain organoid platform integrating AI-based analytics

The 3D-BrAIn project aims to develop a personalized bio-digital twin of the human brain using advanced organoid cultures and machine learning to enhance precision medicine for CNS disorders.

€ 1.998.347